Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Semprus BioSciences Names Two New Executives

Semprus BioSciences has appointed Donald Anderson to the position of vice president of business development, and Laurence Roth to the position of vice president of product development, where both appointments are effective immediately.

The company said that prior to accepting the appointment, Anderson has been managing director of Boston-based Cavan Partners, a life science consulting firm, which he co-founded in 2002. He served as a consultant to Semprus BioSciences since 2008 at Boston.

Reportedly, from 2000-2002, he was vice president of marketing and business development for Biosphere Medical. He co-founded two medical device start-up companies where he worked collaboratively to take one company through the IPO process, and another through an acquisition by Edwards Lifesciences. He has held senior executive positions in sales and marketing from 1979-95 with Wyeth, and a vascular access division of Pfizer.

Before joining Semprus Biosciences, Roth served as an independent medical device industry consultant, providing product development and business strategy services to development stage companies. Roth held executive roles in product development, business development and operations for three venture-backed device companies in the Boston area Arsenal Medical, Percardia, and Focal (acquired by Genzyme) since 1992. He began his career at C R Bard, where he held a variety of engineering and project management positions over 13 years.

David Lucchino, co-founder and chief executive officer of Semprus Biosciences, said: “Don and Larry are widely recognized for their impressive, proven track records in the medical device industry and will be valuable additions to our expanding management team. Their vast business and product development experience are an ideal fit with Semprus BioSciences as we deliver our proprietary ‘super biomaterial’, Semprus Surface, to the vascular access market and beyond.”